BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Inflammatory Bowel Disease Drug Meets Phase 3 Targets


2/21/2012 7:13:29 AM

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI I pivotal Phase 3 trial evaluating vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including TNFa antagonists. Patients received a year of vedolizumab (MLN0002) or placebo treatment, starting with six weeks of induction therapy. Both phases of the trial met their primary endpoints, providing statistically significant improvements in clinical response in the induction phase and clinical remission in the maintenance phase.

The most common adverse events (>10 percent) reported in both the vedolizumab arm and the placebo arm were colitis, headache and nasopharyngitis.

“We are very pleased with the outcomes of this pivotal trial, and the potential that vedolizumab holds for patients with this debilitating disease,” said Tadataka Yamada, M.D., Chief Medical and Scientific Officer, Takeda. “We thank the patients and investigators for their engagement and participation in this clinical evaluation of vedolizumab.”

Detailed results will be presented at an upcoming medical congress.

About GEMINI I

The randomized, placebo-controlled, double-blind GEMINI I Phase 3 study enrolled 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, at more than 210 sites in more than 34 countries.

About Vedolizumab

Vedolizumab is an investigational humanized monoclonal antibody against a4ß7 integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis and Crohn’s disease.

About Ulcerative Colitis

Ulcerative colitis is a chronic relapsing-remitting condition, caused by an overactive inflammatory response in the gastrointestinal tract. Common symptoms include diarrhea, rectal bleeding, incontinence, abdominal pain, fever, malaise and weight loss.

About Takeda

Located in Osaka, Japan, Takeda Pharmaceutical Company Limited (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

Contact:

Takeda Pharmaceutical Company Limited

Media and Investors

Seizo Masuda, + 81-3-3278-2037

seizo.masuda@takeda.com

or

US Media

Manisha Pai, +1 617-551-7877

manisha.pai@mpi.com




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->